INBX
Inhibrx, Inc. [INBX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INBX Stock Summary
Top 10 Correlated ETFs
INBX
Top 10 Correlated Stocks
INBX
In the News
INBX Financial details
Company Rating
Neutral
Market Cap
1.66B
Income
-241.14M
Revenue
1.8M
Book val./share
0.81
Cash/share
5.14
Dividend
-
Dividend %
-
Employees
166
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-9.08
Forward P/E
-
PEG
-2.33
P/S
3901.48
P/B
13.21
P/C
6.68
P/FCF
-10.19
Quick Ratio
9.44
Current Ratio
10.16
Debt / Equity
4.8
LT Debt / Equity
4.76
-
-
EPS (TTM)
-5.03
EPS next Y
-
EPS next Q
-
EPS this Y
41.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
29.42%
Revenue last 5Y
-27.67%
Revenue Q/Q
1273.11%
EPS Q/Q
57.27%
-
-
-
-
SMA20
-
SMA50
-7.89%
SMA100
66.67%
Inst Own
73.44%
Inst Trans
0.89%
ROA
-51%
ROE
-424%
ROC
-0.49%
Gross Margin
100%
Oper. Margin
-37825%
Profit Margin
-42829%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
14.305-39.79
52W High
-11.97%
52W Low
+145.21%
RSI
37
Rel Volume
0.17
Avg Volume
734.08K
Volume
121.52K
Perf Week
-1.97%
Perf Month
-3.4%
Perf Quarter
136.76%
Perf Half Y
94.06%
-
-
-
-
Beta
2.915
-
-
Volatility
0.2%, 0.23%
Prev Close
-0.35%
Price
34.33
Change
-0.92%
INBX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.25 | 0.51 | 0.19 | 0.05 | 0.04 | |
| Net income per share | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | |
| Operating cash flow per share | -0.88 | -1.9 | -2.11 | -2.87 | -4.1 | |
| Free cash flow per share | -0.93 | -1.95 | -2.14 | -2.89 | -4.2 | |
| Cash per share | 0.32 | 5.09 | 3.45 | 6.83 | 5.9 | |
| Book value per share | -2.56 | 2.99 | 1.38 | 1.45 | 0.92 | |
| Tangible book value per share | -2.56 | 2.99 | 1.38 | 1.45 | 0.92 | |
| Share holders equity per share | -2.56 | 2.99 | 1.38 | 1.45 | 0.92 | |
| Interest debt per share | 1.3 | 1.91 | 2.04 | 5.49 | 5.11 | |
| Market cap | 754.12M | 832.86M | 1.66B | 988.26M | 1.79B | |
| Enterprise value | 784.31M | 741.65M | 1.6B | 916.47M | 1.72B | |
| P/E ratio | -14.67 | -11.01 | -20.3 | -6.8 | -7.42 | |
| Price to sales ratio | 82.93 | 65.03 | 232.97 | 453.75 | 994.97 | |
| POCF ratio | -23.51 | -17.36 | -20.67 | -8.57 | -9.26 | |
| PFCF ratio | -22.25 | -16.88 | -20.45 | -8.52 | -9.05 | |
| P/B Ratio | -8.06 | 11.04 | 31.69 | 17.02 | 41.17 | |
| PTB ratio | -8.06 | 11.04 | 31.69 | 17.02 | 41.17 | |
| EV to sales | 86.25 | 57.9 | 224.43 | 420.78 | 957.31 | |
| Enterprise value over EBITDA | -18.41 | -11 | -20.89 | -7.1 | -7.9 | |
| EV to operating cash flow | -24.45 | -15.46 | -19.91 | -7.95 | -8.91 | |
| EV to free cash flow | -23.14 | -15.03 | -19.7 | -7.9 | -8.71 | |
| Earnings yield | -0.07 | -0.09 | -0.05 | -0.15 | -0.13 | |
| Free cash flow yield | -0.04 | -0.06 | -0.05 | -0.12 | -0.11 | |
| Debt to equity | -0.45 | 0.5 | 1.38 | 3.51 | 4.8 | |
| Debt to assets | 1.58 | 0.26 | 0.48 | 0.7 | 0.68 | |
| Net debt to EBITDA | -0.71 | 1.35 | 0.79 | 0.56 | 0.31 | |
| Current ratio | 0.76 | 4.21 | 6.2 | 10.17 | 5.25 | |
| Interest coverage | -7.64 | -6.24 | -14.68 | -8.02 | -6.89 | |
| Income quality | 0.62 | 0.63 | 0.98 | 0.79 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.99 | 0.53 | 1.73 | 9.7 | 16.32 | |
| Research and developement to revenue | 5.27 | 5.74 | 10.03 | 50.59 | 105.92 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.06 | 0.03 | 0.01 | 0.01 | 0.02 | |
| Capex to revenue | -0.2 | -0.11 | -0.12 | -0.31 | -2.55 | |
| Capex to depreciation | -1.56 | -1.34 | -0.72 | -0.56 | -3.86 | |
| Stock based compensation to revenue | 0.44 | 0.39 | 2.11 | 9.39 | 13.8 | |
| Graham number | 9 | 14.19 | 8.17 | 10.86 | 10.31 | |
| ROIC | 1.01 | -0.56 | -0.58 | -0.48 | -0.86 | |
| Return on tangible assets | -1.94 | -0.53 | -0.54 | -0.5 | -0.78 | |
| Graham Net | -2.92 | -0.15 | 0.88 | 1.03 | 0.3 | |
| Working capital | -5.01M | 100.77M | 116.66M | 252.92M | 239.05M | |
| Tangible asset value | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M | |
| Net current asset value | -104.5M | 63.91M | 41.05M | 47.68M | 30.97M | |
| Invested capital | -0.45 | 0.5 | 1.38 | 3.51 | 4.8 | |
| Average receivables | 564K | 526.5K | 746.5K | 567.5K | 517.5K | |
| Average payables | 4.82M | 8.29M | 11.29M | 8.73M | 9.64M | |
| Average inventory | 2.76M | -63.04M | -65.08M | -567.5K | -128.5K | |
| Days sales outstanding | 17.58 | 17.53 | 44.98 | 43.07 | 157.76 | |
| Days payables outstanding | 23.73 | 66.84 | 1.24K | 1.07K | 3.36K | |
| Days of inventory on hand | 24.43 | -642.04 | -119.22 | -32.96 | 0 | |
| Receivables turnover | 20.76 | 20.83 | 8.12 | 8.47 | 2.31 | |
| Payables turnover | 15.38 | 5.46 | 0.29 | 0.34 | 0.11 | |
| Inventory turnover | 14.94 | -0.57 | -3.06 | -11.07 | 0 | |
| ROE | 0.55 | -1 | -1.56 | -2.5 | -5.55 | |
| Capex per share | -0.05 | -0.05 | -0.02 | -0.02 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0 | 0 | 0.03 | |
| Net income per share | -0.95 | -1.12 | -1.08 | -1.1 | -1.73 | |
| Operating cash flow per share | -0.71 | -0.92 | -0.97 | -1.15 | -1.05 | |
| Free cash flow per share | -0.71 | -0.92 | -0.98 | -1.17 | -1.12 | |
| Cash per share | 6.33 | 5.38 | 4.41 | 7.15 | 5.14 | |
| Book value per share | 1.34 | 0.35 | -0.57 | 2.75 | 0.81 | |
| Tangible book value per share | 1.34 | 0.35 | -0.57 | 2.75 | 0.81 | |
| Share holders equity per share | 1.34 | 0.35 | -0.57 | 2.75 | 0.81 | |
| Interest debt per share | 4.84 | 4.83 | 4.96 | 4.58 | 4.02 | |
| Market cap | 1.07B | 822.26M | 1.13B | 865.22M | 2.05B | |
| Enterprise value | 994.33M | 791.27M | 1.15B | 733.61M | 1.99B | |
| P/E ratio | -6.51 | -4.22 | -6.02 | -4.18 | -5.48 | |
| Price to sales ratio | 3.89K | 48.37K | 37.76K | 7.27K | 1.26K | |
| POCF ratio | -34.84 | -20.59 | -26.78 | -15.95 | -36.14 | |
| PFCF ratio | -34.54 | -20.57 | -26.58 | -15.72 | -34.07 | |
| P/B Ratio | 18.36 | 54.34 | -45.66 | 6.68 | 47.2 | |
| PTB ratio | 18.36 | 54.34 | -45.66 | 6.68 | 47.2 | |
| EV to sales | 3.63K | 46.55K | 38.3K | 6.16K | 1.22K | |
| Enterprise value over EBITDA | -28.01 | -18.08 | -29.58 | -16.01 | -22.57 | |
| EV to operating cash flow | -32.49 | -19.81 | -27.17 | -13.52 | -34.94 | |
| EV to free cash flow | -32.21 | -19.8 | -26.96 | -13.32 | -32.95 | |
| Earnings yield | -0.04 | -0.06 | -0.04 | -0.06 | -0.05 | |
| Free cash flow yield | -0.03 | -0.05 | -0.04 | -0.06 | -0.03 | |
| Debt to equity | 3.51 | 13.56 | -8.41 | 1.6 | 4.8 | |
| Debt to assets | 0.7 | 0.81 | 0.98 | 0.56 | 0.68 | |
| Net debt to EBITDA | 2.02 | 0.71 | -0.41 | 2.87 | 0.77 | |
| Current ratio | 10.17 | 7.47 | 6.49 | 10.16 | 5.25 | |
| Interest coverage | -6.64 | -8.62 | -5.23 | -5.62 | -10.74 | |
| Income quality | 0.75 | 0.82 | 0.9 | 1.05 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 19.43 | 376.29 | 242.1 | 66.29 | 4.79 | |
| Research and developement to revenue | 111.14 | 2.2K | 1.14K | 319.81 | 50.09 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0.01 | 0.01 | 0.06 | |
| Capex to revenue | -0.97 | -1.35 | -10.57 | -6.82 | -2.11 | |
| Capex to depreciation | -0.88 | -0.08 | -1.08 | -2.67 | -11.55 | |
| Stock based compensation to revenue | 19.54 | 331.53 | 208.43 | 54.87 | 3.93 | |
| Graham number | 5.34 | 2.95 | 3.71 | 8.24 | 5.6 | |
| ROIC | -0.13 | -0.19 | -0.22 | -0.13 | -0.35 | |
| Return on tangible assets | -0.14 | -0.19 | -0.22 | -0.14 | -0.3 | |
| Graham Net | 0.95 | -0.1 | -0.92 | 2 | 0.26 | |
| Working capital | 252.92M | 211.14M | 171.99M | 327.53M | 239.05M | |
| Tangible asset value | 58.06M | 15.13M | -24.81M | 129.6M | 43.5M | |
| Net current asset value | 47.68M | 5.19M | -34.66M | 120.16M | 30.97M | |
| Invested capital | 3.51 | 13.56 | -8.41 | 1.6 | 4.8 | |
| Average receivables | 286K | 280.5K | 315.5K | 329K | 554.5K | |
| Average payables | 8.45M | 9.62M | 10.31M | 8.78M | 9.41M | |
| Average inventory | -286K | -280.5K | 4.94M | 4.92M | -165.5K | |
| Days sales outstanding | 84.42 | 1.61K | 981 | 250.34 | 42.85 | |
| Days payables outstanding | 1.04K | 1.36K | 1.19K | 2.33K | 3.31K | |
| Days of inventory on hand | -32.13 | -37.89 | 1.25K | -97.99 | 0 | |
| Receivables turnover | 1.07 | 0.06 | 0.09 | 0.36 | 2.1 | |
| Payables turnover | 0.09 | 0.07 | 0.08 | 0.04 | 0.03 | |
| Inventory turnover | -2.8 | -2.38 | 0.07 | -0.92 | 0 | |
| ROE | -0.7 | -3.22 | 1.9 | -0.4 | -2.15 | |
| Capex per share | -0.01 | 0 | -0.01 | -0.02 | -0.06 |
INBX Frequently Asked Questions
What is Inhibrx, Inc. stock symbol ?
Inhibrx, Inc. is a US stock , located in La jolla of Ca and trading under the symbol INBX
What is Inhibrx, Inc. stock quote today ?
Inhibrx, Inc. stock price is $34.33 today.
Is Inhibrx, Inc. stock public?
Yes, Inhibrx, Inc. is a publicly traded company.
Company Profile
- Volume Average 734.08K
- Market Capitalization 1.66B
- Employee 166
- CEO Mr. Mark Paul Lappe
- Headquarters La Jolla,CA,US
- IPO Date 2020-08-19
-
Website
https://inhibrx.com 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
